The first and only clinically validated circulating TTMV® DNA blood test that aids in the detection of HPV-driven cancer.

Intervene earlier.

NavDx® is the first and only clinically validated circulating tumor-tissue-modified HPV (TTMV) DNA blood test that can aid in the detection of HPV-driven cancer.¹

 

NavDx uncovers the presence of HPV+ cancer across the patient care continuum, so treating physicians can intervene earlier, which may result in improved outcomes.¹¯³ Use NavDx to optimize clinical management across the care continuum by:

  • Confirming the tumor HPV genotype²
  • Assessing current treatment response¹
  • Identifying molecular residual disease post-treatment¹
  • Detecting recurrences earlier than the current standard-of-care surveillance schedule¹⋅³

The clinical utility of NavDx has been validated in a 3-year longitudinal study and proven in real-world practice.¹

This innovative and accessible blood test enables you to optimize HPV-driven cancer care and reassure patients that their disease is being effectively monitored.¹

Detect recurrence before a PET or CT.

Uncover the presence of HPV+ head and neck cancer across the care continuum.

NavDx® lets you optimize clinical management of HPV-driven cancer by accurately assessing treatment response, identifying the presence of post-treatment molecular residual disease, and conveniently monitoring for recurrence.¹

  • Distinguish tumor-tissue-modified HPV (TTMV®) DNA from non-cancerous sources of HPV DNA²
  • Verify the presence of molecular residual disease post-treatment, to identify and prioritize patients appropriate for adjuvant or follow-on chemoradiation treatment¹
  • Safely surveil based on highly accurate positive (94%) and negative (100%) predictive values for active HPV-driven malignancy¹
  • Accurately detect recurrence a median of 4 months earlier than it would present clinically via PET or CT scan to facilitate earlier initiation of salvage therapy¹

NavDx enables physicians to optimize HPV-driven cancer care and reassure patients that their disease is being effectively monitored.¹

Optimize HPV+ cancer care with NavDx to:

CONFIRM

the tumor HPV genotype²

ASSESS

treatment response¹

IDENTIFY

the presence of post-treatment molecular residual disease, and accurately¹

DETECT

recurrence significantly earlier than it would present clinically¹⁻³

Reliable and easy reporting.

The easy-to-interpret, actionable test report helps inform clinical decisions, enabling physicians to intervene earlier, which may result in improved outcomes.¹
  • >95% sensitivity for recurrence detection, as validated in a 3-year prospective clinical study¹
  • >99% probability of being recurrence-free as long as TTMV HPV DNA remains undetectable after treatment¹
  • Detects recurrences earlier than the current standard-of-care surveillance schedule¹˒³
  • Reports are issued within 7 calendar days from sample receipt by the Naveris lab

References: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058. 2. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. 2019;25(15):4682-4690. 3. Head and neck cancers. Version 3.2021. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2021; https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.

Get Started with NavDx